Gilead Sciences (GILD) stock fell after The Wall Street Journal reported that the Health and Human Services Department is looking at ...

Roche executive Daniel O’Day is to take the helm at Gilead after John Milligan steps down as CEO at the end of this year, the company has announced. Currently CEO of Roche Pharmaceuticals since ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

In fact, Gilead Sciences(NASDAQ ... a first-line treatment for metastatic triple-negative breast cancer. CEO Daniel O'Day told analysts on the Q4 earnings call: As we shared at our HIV analyst ...

Gilead Sciences has revealed its pricing plans for coronavirus drug remdesivir – and the rationale behind its decision. In an open letter, the company’s chief executive Daniel O’Day reveals ...